DexCom, Inc. (DXCM)
| Market Cap | 53.22B |
| Revenue (ttm) | 2.17B |
| Net Income (ttm) | 530.60M |
| Shares Out | 96.70M |
| EPS (ttm) | 5.34 |
| PE Ratio | 105.06 |
| Forward PE | 156.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 89,491 |
| Open | 553.78 |
| Previous Close | 556.54 |
| Day's Range | 550.00 - 561.19 |
| 52-Week Range | 305.63 - 579.00 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 544.10 (-3.0%) |
| Est. Earnings Date | Oct 28, 2021 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LL...
Financial Performance
In 2020, DexCom's revenue was $1.93 billion, an increase of 30.54% compared to the previous year's $1.48 billion. Earnings were $493.60 million, an increase of 388.23%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for DexCom stock is "Buy." The 12-month stock price forecast is 544.10, which is a decrease of -2.98% from the latest price.
News
2 Unstoppable Stocks to Buy and Hold for Decades
These are investments that you won't need to worry about.
Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK
LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an awarenes...
Got $1,000? These 2 High-Growth Stocks Are Screaming Buys Right Now
Both companies are in industries with strong opportunity ahead.
Here's Why You Should Add DexCom (DXCM) Stock to Your Portfolio
Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.
Stocks Rebound, But Will Rally Attempt Have Legs? Datadog, Microsoft, Dexcom Show Strength
Stocks rebound, but will rally attempt have legs? Datadog, Microsoft, Dexcom show strength.
Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time.
3 Innovative Growth Stocks That'll Make You Richer Through 2025
Their products are better than those of their rivals, and their leads are increasing.
Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba
Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.
1 Supercharged Healthcare Stock to Buy Right Now
The stock isn't a household name, but it's generated multibagger returns over the past five years alone.
This Stock Is Likely To Outperform Abbott Laboratories
We think that Dexcom stock currently is a better pick compared to Abbott stock, despite Dexcom being more expensive of the two. Dexcom trades at about 25x trailing revenues, compared to just 5x for Abbott.
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People With Type 1 Diabetes
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom G6 Continuous Glucose Monitoring System now Covered in Manitoba for Young People With Type 1 Diabetes
Ignore GameStop: Here Are 2 Better Stocks
The performance of these two companies isn't detached from their financial results.
Will Dexcom Stock Continue To Make Fresh Highs?
A few months back we discussed that going by its historical performance Dexcom Stock may continue to rally after a 23% rise in a month. DXCM stock has since rallied 34%, while it is up 11% over the last...
5 Medtech Stocks to Seize Major Growth
The merging of healthcare and technology is changing how we care for our bodies. It's also creating investment opportunities, such as these five medical technology stocks.
2 Sizzling Hot Stocks to Buy Right Now
These two stocks could make you richer in 2021 and beyond.
Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients
Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.
Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adoles...
BURNABY, British Columbia--(BUSINESS WIRE)--Non-Insured Health Benefits Program now Covers Dexcom G6 CGM System for Children and Adolescents on Intensive Insulin Therapy
This Smart Monitor Company Has Outperformed Apple, Google And Amazon Over The Last 5 Years
A smart monitor company that received FDA approval in 2015 has seen a five-year stock performance that has outperformed the returns of Apple Inc (NASDAQ: AAPL), Alphabet Inc (NASDAQ: GOOG)(NASDAQ: GOOGL...
3 Growth Stocks That'll Make You Richer By 2024
Their competition is in the rearview mirror, and customers are clamoring for their products.
Dexcom Announces Upcoming Virtual Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations
Senseonic Stock Is Climbing After Bouncing Back From a Disappointing Q2
Despite a mixed Q2 2021 result, bullish sentiment is building for Senseonics. Here's why SENS stock can run-up in the future.
Moderna And DexCom Lead The Nasdaq-100
U.S. indices had a mixed day of trading Wednesday as investors weigh rising COVID-19 Delta variant cases nationwide. The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) gained 0.17% to $380.58
DexCom And O'Reilly Auto Parts Lead The QQQ Monday
U.S. indices bounced off Monday morning's lows as investors weigh weak China retail and production data. Uncertainty around the COVID-19 Delta variant is also weighing on the market.
3 Growth Stocks to Buy and Hold Regardless of What Happens With the Delta Variant
These companies are still going to be great long-term buys.